Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial
Medicina · 2024
DOI: 10.3390/medicina60060985 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Medicina, 2024. Verfasst von Sònia Travé-Huarte und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Amnion. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NuVision and the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre.
Abstract (Originalsprache)
Background and Objectives: Dry Eye Disease (DED) is a chronic condition characterised by tear film instability and ocular surface disruption, significantly impacting patients’ quality of life. This study aimed to provide top-level clinical evidence for the long-term efficacy of dehydrated amniotic membrane (dAM, Omnigen®) delivered via a specialised bandage contact lens (sBCL, OmniLenz) for managing moderate-to-severe DED. Materials and Methods: This randomised controlled trial (NCT04553432) involved 93 participants with moderate-to-severe DED, randomised to receive a 1-week bilateral treatment of either dAM (17 mm diameter with 6 mm central ‘window’) applied under a sBCL or sBCL alone. Participants were assessed at baseline and followed up at 1, 3, and 6 months post-treatment. Outcomes included changes in symptomatology, tear film and ocular surface measurements, and in vivo confocal microscopy imaging of corneal nerve parameters and corneal dendritic cell (CDC) counts.
Results
The dAM-sBCL group demonstrated a 65% reduction in OSDI scores at 6 months (p < 0.001), with 88% of participants showing improvement at 1 month. Corneal staining was significantly reduced in both groups. dAM-sBCL provided significant improvements in corneal nerve parameters at 1 month, with sustained positive trends at 3 months. Additionally, dAM-sBCL significantly reduced mature CDC counts, suggesting an anti-inflammatory effect.
Conclusions
Treatment with dAM-sBCL for just 1 week significantly and rapidly improved dry eye symptoms as well as ocular surface signs for at least 3 months. It also enhanced corneal nerve health while reducing activated/mature corneal inflammatory cell numbers, presenting a safe and promising new treatment for moderate-to-severe DED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK.
ORCID-Profile: Sònia Travé-Huarte, James S Wolffsohn
Förderung
- NuVision and the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre
Zitieren
APA
Travé-Huarte, S., & Wolffsohn, J. S. (2024). Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial. Medicina. https://doi.org/10.3390/medicina60060985
Vancouver
Travé-Huarte S, Wolffsohn JS. Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial. Medicina. 2024. doi:10.3390/medicina60060985
BibTeX
@article{TravHuarte2024,
author = {Travé-Huarte, Sònia and Wolffsohn, James S},
title = {Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial},
journal = {Medicina},
year = {2024},
doi = {10.3390/medicina60060985}
}
EUVIMED